Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anemia and risk of dementia in the general population: a propensity-score based cohort study.

Scientific reports·2026
Same author

JAK-STAT3-MYC axis defines pathogenic stem cell-like memory CD4<sup>+</sup> T cells in rheumatoid arthritis.

Clinical immunology (Orlando, Fla.)·2026
Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026
Same author

Clinical, serological and haemodynamic factors associated with poor outcomes in systemic lupus erythematosus-associated pulmonary arterial hypertension: a multicentre retrospective study from Korea.

Rheumatology (Oxford, England)·2026
Same author

Development and validation of a risk score for serious infection in patients with rheumatic diseases receiving prolonged high-dose glucocorticoids.

Arthritis research & therapy·2026
Same author

Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial.

Annals of the rheumatic diseases·2026

Related Experiment Video

Updated: Jul 11, 2026

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
08:57

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

Associations between interferon regulatory factor-1 polymorphisms and Behçet's disease.

Yun Jong Lee1, Seong Wook Kang, Ju Kyoung Song

  • 1Department of Internal Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.

Human Immunology
|September 18, 2007
PubMed
Summary

Interferon regulatory factor-1 (IRF-1) gene variations are linked to Behçet

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Experiment Videos

Last Updated: Jul 11, 2026

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
08:57

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Vascular Biology

Background:

  • Behçet's disease (BD) is an idiopathic systemic vasculitis often associated with thrombotic events.
  • Infectious agents are suspected triggers for BD pathogenesis.
  • Interferon regulatory factor-1 (IRF-1) is a key transcription factor in immune responses.

Purpose of the Study:

  • To investigate the association between IRF-1 gene polymorphisms and Behçet's disease.
  • To explore the relationship between IRF-1 haplotypes and disease susceptibility, particularly in women.
  • To determine if IRF-1 polymorphisms correlate with thrombotic complications in BD patients.

Main Methods:

  • Genotyping of IRF-1 promoter (-415 C/A, -410 A/G, -300 A/G) and 3'-UTR (A/G) polymorphisms.
  • Case-control study comparing 105 BD patients with 105 healthy controls.
  • Haplotype analysis and statistical evaluation including odds ratios and confidence intervals.

Main Results:

  • The AGGG haplotype was significantly more frequent in BD patients (73.5%) compared to controls (60.2%).
  • The CAAG haplotype was significantly less frequent in BD patients (2.2%) than in controls (9.5%).
  • In female BD patients, AGGG haplotype was higher and CAAG haplotype was lower compared to female controls.
  • The CAAA haplotype was associated with increased risk of deep vein thrombosis (DVT) and thrombotic events in BD patients.

Conclusions:

  • IRF-1 may be a novel susceptibility gene for Behçet's disease, especially in women.
  • Specific IRF-1 polymorphisms, particularly the CAAA haplotype, are associated with an increased risk of thrombosis in BD.
  • IRF-1 gene variations could play a role in the pathogenesis of thrombotic complications in Behçet's disease.